NCT04378296: TELEDERMA

Economic Evaluation in Teledermatology

Completed NA Last updated 18 May 2022

What this trial tests

NA trial testing Teledermatology in Skin Diseases in 450 participants. Completed in 30 April 2022.

Timeline

1 April 2021

Primary endpoint
31 October 2021

30 April 2022

Quick facts

Lead sponsor	Antonio Lopez Villegas
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	450
Start date	1 April 2021
Primary completion	31 October 2021
Estimated completion	30 April 2022
Sites	2 locations across Spain

Drugs / interventions tested

• Teledermatology

Conditions studied

• Skin Diseases — all drugs for Skin Diseases →

Sponsor

Antonio Lopez Villegas

Who can join

18 and older, any sex, with Skin Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Introduction: Previous studies confirm that teledermatology allows the generation of a quick response from the specialist's consultation, reduction of unnecessary travels, early diagnosis and priority in the attention to the most urgent cases. Despite these advantages and that teledermatology has experienced exponential growth since its introduction approximately 16 years ago in Spain, in Andalusia, its use is still very limited. The objective of this project will be to carry out an analysis of the quality of life related to health, costs, cost-utility and informal care of teledermatology services in Primary Care compared to conventional monitoring carried out at the Hospital de Poniente.

Methodology: A randomized, controlled, unmasked, inter-level clinical trial (Primary Care-Hospital de Poniente) and multicentre (all health centers attached to the Poniente Health District of Almería) will be carried out with a 6-month follow-up. Patients will be assigned to the teledermatology group (experimental) or the conventional monitoring group in the hospital (control). The patients included in the experimental group will be monitored asynchronously. Baseline characteristics, number of visits to the hospital, health-related quality of life, costs, informal care and satisfaction from the perspective of the Andalusian Public Health System and patients and their caregivers will be analyzed. The generic EuroQol-5D questionnaire (EQ-5D) will be administered to assess health-related quality of life and the SKINDEX-29 quality of life dermatological questionnaire. A cost-utility analysis will be performed to assess whether tele-dermatology is cost-effective in terms of additional cost for additional quality-adjusted life years (QALYs).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Comparative Analysis of Quality of Life of Patients with Dermatological Problems: Teledermatology Versus Face-to-Face Dermatology.
   Lopez-Liria R, Lopez-Villegas A, Valverde-Martinez MA, Perez-Heredia M, et al · · 2022 · cited 5× · PMID 36360514 · DOI 10.3390/healthcare10112172
2. Patients' Experiences and Communication with Teledermatology versus Face-to-Face Dermatology.
   Leal-Costa C, Lopez-Villegas A, Perez-Heredia M, Baena-Lopez MA, et al · · 2022 · cited 5× · PMID 36233398 · DOI 10.3390/jcm11195528